Companies /Healthcare

Danaher Corp

NYSE: DHR Diagnostics & Research
$232.23
▼ $4.75 (−2.00%) today
Markets closed · 11:10pm ET

24/7 Wall St. View

Price Prediction $283.48 +22.1% Our analysts’ 12-month view: target, optimistic case, and floor. DHR price prediction → Earnings Beat +10.0% EPS vs. the estimate, revenue, and how the market reacted. DHR earnings history →

DHR at a Glance

Valuation
Market cap
$163.3B
P/E ratio
38.5
Dividend yield
0.64%
Profitability
Revenue (TTM)
$25.6B
Profit margin
16.9%
EPS (TTM)
$6.04
Price
52-week range
$160 – $241
24/7 target
$283.48
Street target
$259.90
Earnings
Next report
Jan 26, 2027
Q3 2026 EPS
$2.11
vs. $1.92 est.
+10.0%

Headquartered in Washington, DC Fiscal year ends December NYSE: DHR danaher.com

About Danaher

Danaher Corporation is a global life sciences and diagnostics company operating through three segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment provides tools and technologies for bioprocessing and biopharmaceutical development. Life Sciences offers instruments, consumables, and software for research, clinical, and applied markets. The Diagnostics segment delivers clinical instruments, reagents, and molecular diagnostics solutions including respiratory testing products. The company completed the acquisition of Masimo Corporation, expanding its diagnostics capabilities. Danaher employs approximately 60,000 associates worldwide and operates using the Danaher Business System (DBS), a proprietary continuous improvement methodology focused on operational excellence. The company serves pharmaceutical, biotech, academic research, clinical laboratory, and healthcare customers globally. Updated

Latest Activity

DHRDanaher
Regular session
$230.40
+5.22%open $218.97

A 5.2% jump to $230.40 is an outsized day for a $162 billion life sciences name, and it lands with earnings due today. That sets a high bar for the report to clear.

Read more
DHRDanaher
Regular session
$231.48
+5.71%open $218.97

A 5.7% intraday jump to $231.48 is a rare one-day move for a $163 billion life sciences name, and it lands on the same day Danaher reports earnings. The results and outlook now have to justify the repricing.

Read more
DHRDanaher Corporation
Reports Wed Oct 21Before open6:00 AM ETConfirmed

Danaher reports at 6:00 AM ET with a six-quarter EPS beat streak on the line, and consensus sits at $1.92. Bioprocessing commentary here sets the tone for the entire life science tools group.

    Read more
    New insider tie · Form 3Robert Hershberg
    Now director at DANAHER CORP /DE/

    A new name on the board of a $161 billion life sciences giant is worth tracking, because board seats at Danaher tend to precede capital allocation shifts in diagnostics and biotech tools. Hershberg's first Form 3 puts his future buys and sells on the public record from here on.

    Read more
    New insider tie · Form 3Daniel L Comas
    Now director at DANAHER CORP /DE/

    Danaher's former longtime finance chief is back inside the house, this time in the boardroom, just as the $161 billion group digests its $10 billion Masimo purchase. An insider who knows the company's capital allocation playbook cold now has a vote on the next deal.

    Read more
    Polymarket@polymarket

    Danaher is moving from selling lab instruments to running the lab itself, putting its AI ambitions directly against drug-discovery software rivals.

    JUST IN: Danaher unveils plans for an autonomous AI research lab combining robotics and AI to design, build, & test new molecules with minimal human intervention.
    • Replies9
    • Reposts5
    • Likes37
    Read more
    Biggest movers · At the close
    Gainers
    • ACNAccenture$211.97+15.6%
    • SNPSSynopsys$490.81+12.8%
    • COHRCoherent$318.52+10.7%
    • AAOIApplied Optoelectronics$107.16+8.0%
    • LITELumentum$1,043.95+7.5%
    Losers
    • AMCAMC Entertainment$2.75-8.2%
    • TEMTempus AI$76.51-6.6%
    • BRKRBruker$61.76-4.6%
    • DHRDanaher$211.34-4.6%
    • NWGNatWest Group$17.36-4.3%

    Three names in our 383-stock board closed with double-digit gains, led by Accenture's 15.6% jump to $211.97, a move that size is rare for a mega-cap consultant. The downside was far tamer, with AMC's 8.2% slide the worst of it.

    Read more

    DHR Coverage

    10:20am ET
    Investing

    How to Invest in Water in 3 Steps

    24/7 Wall Street Insights Water is essential for life, and as such, water is and has been the most precious commodity on the planet since time immemorial. The stocks of companies involved…

    DHR ECL ROP
    John Seetoo
    Load More

    Frequently Asked Questions

    What does Danaher do?

    Danaher Corporation is a global life sciences and diagnostics company operating through three segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment provides tools and technologies for bioprocessing and biopharmaceutical development.

    What is the DHR stock price target?

    24/7 Wall St.'s 12-month price target for DHR is $283.48, rated Buy. The Wall Street consensus target is $259.90. DHR price prediction →